Author Page for Martina Garau

Office of Health Economics, Office of Health Economics, University of Washington, University of Washington and Novartis Institutes for Biomedical Research, Cambridge - Novartis Pharma AG

Downloads 130 (444,338)

Citation 6

Abstract:

5.

Estimating Pharmaceutical Companies’ Value to the National Economy - Case Study of the British Pharma Group

OHE, February 2007

Number of pages: 20 Posted: 27 Aug 2015

Martina Garau and Jon Sussex

Office of Health Economics and RAND Europe

Downloads 98 (547,388)

Abstract:

6.

Exploring the Interdependencies of Research Funders in the UK

Number of pages: 161 Posted: 16 Aug 2015 Last Revised: 24 Oct 2015

Koonal Shah, Jon Sussex, Karla Hernandez-Villafuerte, Martina Garau, Daniele Rotolo, Michael M. Hopkins, Nicola Grassano, Phillipa Crane, Frederique Lang, Joshua Moon, C. Pateman, Abigail Mawer, Chris Farrell and Tammy-Ann Sharp

Office of Health Economics, RAND Europe, Office of Health Economics, Office of Health Economics, SPRU (Science Policy Research Unit), University of Sussex, University of Sussex, University of Sussex, University of Sussex, SPRU (Science Policy Research Unit) - University of Sussex, Science Policy Research Unit (SPRU), University of Sussex - Science and Technology Policy Research Unit (SPRU), University of Sussex - Science and Technology Policy Research Unit (SPRU), University of Sussex - Science and Technology Policy Research Unit (SPRU) and University of Sussex - Science and Technology Policy Research Unit (SPRU)

Downloads 55 (747,945)

Citation 1

Abstract:

7.

Using QALYs in Cancer: A Review of the Methdological Limitations

Number of pages: 28 Posted: 22 Aug 2015

Martina Garau, Koonal Shah, Anne Mason, Qing Wang, Adrian Towse and Michael Drummond

Office of Health Economics, Office of Health Economics, University of York, Independent, Office of Health Economics and University of York - Centre for Health Economics

Downloads 54 (754,260)

Abstract:

8.

Is the Link between Health and Wealth Considered in Decision Making? Results from a Qualitative Study

Number of pages: 20 Posted: 16 Aug 2015

Martina Garau, Koonal Shah, Priya Sharma and Adrian Towse

Office of Health Economics, Office of Health Economics, United States Agency for International Development (USAID) and Office of Health Economics

Downloads 34 (905,312)

Abstract:

9.

Modelling the R&D Process for Global Diseases Driven By Public-Private Partnersips (PPPs)

iHEA 2007 6th World Congress: Explorations in Health Economics Paper

Posted: 07 Jul 2007

Paul Fenn, Adrian Towse, Martina Garau, Ed Godber, Alastair Gray and Clive Pritchard

University of Nottingham, Office of Health Economics, Office of Health Economics, Office of Health Economics, University of Oxford - Health Economics Research Centre (HERC) and Office of Health Economics

Martina Garau

Office of Health Economics

9

960

13

Scholarly Papers (9)

Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?

Abstract:

Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries

Abstract:

Multi-Criteria Decision Analysis to Value Orphan Medicines

Abstract:

Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?

Abstract:

Estimating Pharmaceutical Companies’ Value to the National Economy - Case Study of the British Pharma Group

Abstract:

Exploring the Interdependencies of Research Funders in the UK

Abstract:

Using QALYs in Cancer: A Review of the Methdological Limitations

Abstract:

Is the Link between Health and Wealth Considered in Decision Making? Results from a Qualitative Study

Abstract:

Modelling the R&D Process for Global Diseases Driven By Public-Private Partnersips (PPPs)

Abstract:

Other Papers (1)

Donor Investment Choices in Developing Countries: A Methodology and Some Illustrative Results Based on Public-Private Partnerships for Product Development (PD PPPs)

Abstract: